Biomea Fusion, Inc. Debt Securities, Available-for-sale
Biomea Fusion, Inc. (BMEA) had Debt Securities, Available-for-sale of $34.25 million as of 2025-03-31, per its 10-Q filed 2025-05-05.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2025-05-05
- 2025-03-31: Debt Securities, Available-for-sale $34.25M.
- 2024-12-31: Debt Securities, Available-for-sale $56.03M.
- 2024-09-30: Debt Securities, Available-for-sale $84.26M.
- 2024-06-30: Debt Securities, Available-for-sale $111.44M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2025-03-31 | $34.25M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $56.03M 10-Q · filed 2025-05-05 |
| 2024-09-30 | $84.26M 10-Q · filed 2024-10-29 |
| 2024-06-30 | $111.44M 10-Q · filed 2024-07-31 |
| 2024-03-31 | $143.00M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $174.43M 10-K · filed 2025-03-31 |
| 2023-09-30 | $196.84M 10-Q · filed 2023-10-30 |
| 2023-06-30 | $219.47M 10-Q · filed 2023-07-31 |
| 2023-03-31 | $85.26M 10-Q · filed 2023-05-02 |
| 2022-12-31 | $106.83M 10-K · filed 2024-03-28 |
| 2022-09-30 | $120.87M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $128.26M 10-Q · filed 2022-08-01 |
| 2022-03-31 | $137.00M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $141.85M 10-K · filed 2023-03-28 |
| 2021-09-30 | $150.93M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $54.83M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $54.86M 10-Q · filed 2021-05-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |